1. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1-133.
[CROSSREF] [PUBMED] [PMC]
2. Li D, Gao M, Li X, Xing M. Molecular aberrance in papillary thyroid microcarcinoma bearing high aggressiveness: identifying a “Tibetan Mastiff dog” from puppies. J Cell Biochem 2016;117:1491-6.
[CROSSREF] [PUBMED]
3. Nixon IJ, Wang LY, Palmer FL, Tuttle RM, Shaha AR, Shah JP, et al. The impact of nodal status on outcome in older patients with papillary thyroid cancer. Surgery 2014;156:137-46.
[CROSSREF] [PUBMED]
4. Mercante G, Frasoldati A, Pedroni C, Formisano D, Renna L, Piana S, et al. Prognostic factors affecting neck lymph node recurrence and distant metastasis in papillary microcarcinoma of the thyroid: results of a study in 445 patients. Thyroid 2009;19:707-16.
[CROSSREF] [PUBMED]
5. Pisanu A, Saba A, Podda M, Reccia I, Uccheddu A. Nodal metastasis and recurrence in papillary thyroid microcarcinoma. Endocrine 2015;48:575-81.
[CROSSREF] [PUBMED]
6. Perera D, Ghossein R, Camacho N, Senbabaoglu Y, Seshan V, Li J, et al. Genomic and transcriptomic characterization of papillary microcarcinomas with lateral neck lymph node metastases. J Clin Endocrinol Metab 2019;104:4889-99.
[CROSSREF] [PUBMED] [PMC]
7. Jeon MJ, Chun SM, Lee JY, Choi KW, Kim D, Kim TY, et al. Mutational profile of papillary thyroid microcarcinoma with extensive lymph node metastasis. Endocrine 2019;64:130-8.
[CROSSREF] [PUBMED]
8. Lee WK, Lee SG, Yim SH, Kim D, Kim H, Jeong S, et al. Whole exome sequencing identifies a novel hedgehog-interacting protein G516R mutation in locally advanced papillary thyroid cancer. Int J Mol Sci 2018;19:2867.
[CROSSREF] [PMC]
9. Bamshad MJ, Ng SB, Bigham AW, Tabor HK, Emond MJ, Nickerson DA, et al. Exome sequencing as a tool for Mendelian disease gene discovery. Nat Rev Genet 2011;12:745-55.
[CROSSREF] [PUBMED]
10. Biesecker LG, Green RC. Diagnostic clinical genome and exome sequencing. N Engl J Med 2014;370:2418-25.
[CROSSREF] [PUBMED]
11. Masoodi T, Siraj AK, Siraj S, Azam S, Qadri Z, Albalawy WN, et al. Whole-exome sequencing of matched primary and metastatic papillary thyroid cancer. Thyroid 2020;30:42-56.
[CROSSREF] [PUBMED] [PMC]
12. Miller AL, Garcia PL, Pressey JG, Beierle EA, Kelly DR, Crossman DK, et al. Whole exome sequencing identified sixty-five coding mutations in four neuroblastoma tumors. Sci Rep 2017;7:17787.
[CROSSREF] [PUBMED] [PMC]
13. Mareschal S, Dubois S, Viailly PJ, Bertrand P, Bohers E, Maingonnat C, et al. Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma. Genes Chromosomes Cancer 2016;55:251-67.
[CROSSREF] [PUBMED]
15. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 2010;26:589-95.
[CROSSREF] [PUBMED] [PMC]
16. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010;20:1297-303.
[CROSSREF] [PUBMED] [PMC]
17. Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013;31:213-9.
[CROSSREF] [PUBMED] [PMC]
18. Kim S, Scheffler K, Halpern AL, Bekritsky MA, Noh E, Kallberg M, et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat Methods 2018;15:591-4.
[CROSSREF] [PUBMED]
19. Saunders CT, Wong WS, Swamy S, Becq J, Murray LJ, Cheetham RK. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 2012;28:1811-7.
[CROSSREF] [PUBMED]
20. Ramos AH, Lichtenstein L, Gupta M, Lawrence MS, Pugh TJ, Saksena G, et al. Oncotator: cancer variant annotation tool. Hum Mutat 2015;36:E2423-9.
[CROSSREF] [PUBMED] [PMC]
21. Kircher M, Witten DM, Jain P, O’Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 2014;46:310-5.
[CROSSREF] [PUBMED] [PMC]
22. Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res 2018;28:1747-56.
[CROSSREF] [PUBMED] [PMC]
23. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014;159:676-90.
[PUBMED] [PMC]
24. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12:245-62.
[CROSSREF] [PUBMED]
25. Nucera C, Pontecorvi A. Clinical outcome, role of BRAF (V600E), and molecular pathways in papillary thyroid microcarcinoma: is it an indolent cancer or an early stage of papillary thyroid cancer? Front Endocrinol (Lausanne) 2012;3:33.
[PUBMED] [PMC]
26. Choi SY, Park H, Kang MK, Lee DK, Lee KD, Lee HS, et al. The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors. World J Surg Oncol 2013;11:291.
[CROSSREF] [PUBMED] [PMC]
27. Li H, Ganta S, Fong P. Altered ion transport by thyroid epithelia from CFTR(-/-) pigs suggests mechanisms for hypothyroidism in cystic fibrosis. Exp Physiol 2010;95:1132-44.
[PUBMED] [PMC]
28. Wilschanski M, Durie PR. Patterns of GI disease in adulthood associated with mutations in the CFTR gene. Gut 2007;56:1153-63.
[CROSSREF] [PUBMED] [PMC]
29. Johannesson M, Askling J, Montgomery SM, Ekbom A, Bahmanyar S. Cancer risk among patients with cystic fibrosis and their first-degree relatives. Int J Cancer 2009;125:2953-6.
[CROSSREF] [PUBMED]
30. Oh IH, Oh C, Yoon TY, Choi JM, Kim SK, Park HJ, et al. Association of CFTR gene polymorphisms with papillary thyroid cancer. Oncol Lett 2012;3:455-61.
[CROSSREF] [PUBMED]
31. Weber J, de la Rosa J, Grove CS, Schick M, Rad L, Baranov O, et al. PiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in mice. Nat Commun 2019;10:1415.
[CROSSREF] [PUBMED] [PMC]
32. Kunstman JW, Juhlin CC, Goh G, Brown TC, Stenman A, Healy JM, et al. Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing. Hum Mol Genet 2015;24:2318-29.
[CROSSREF] [PUBMED] [PMC]
33. Bhattacharya G, Kalluri R, Orten DJ, Kimberling WJ, Cosgrove D. A domain-specific usherin/collagen IV interaction may be required for stable integration into the basement membrane superstructure. J Cell Sci 2004;117(Pt 2):233-42.
[CROSSREF]
34. Kim N, Hong Y, Kwon D, Yoon S. Somatic mutaome profile in human cancer tissues. Genomics Inform 2013;11:239-44.
[CROSSREF] [PUBMED] [PMC]